DEF: Alumis Inc. Schedules 2025 Annual Stockholders Meeting to Elect Directors and Ratify Auditor

Alumis Inc. has announced its 2025 Annual Meeting of Stockholders, a virtual event set for July 30, 2025, to vote on the re-election of two Class I directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm.

Summary

• Alumis Inc. will hold its 2025 Annual Meeting of Stockholders virtually on Wednesday, July 30, 2025, at 9:00 a.m. Pacific Time.
• Stockholders will vote on two key proposals: the election of Srinivas Akkaraju and Sapna Srivastava as Class I directors to serve until the 2028 Annual Meeting, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends a 'FOR' vote for both proposals.
• The record date for voting eligibility is June 4, 2025, with 96,004,357 shares of voting common stock outstanding.
• The company disclosed executive compensation for 2023 and 2024, with CEO Martin Babler's total compensation increasing from $4,591,749 in 2023 to $10,661,218 in 2024, largely due to option awards.
• Audit fees paid to PricewaterhouseCoopers LLP were $1,691,000 in 2024, up from $786,000 in 2023, with the 2024 fees including costs related to the company's IPO.
• The company completed significant capital raises, including $90 million from Series B-2 and B-2A convertible preferred stock financings in 2023, and approximately $259 million from Series C and C-1 convertible preferred stock financings in 2024.
• A concurrent private placement in July 2024 saw AyurMaya Capital Management Fund, LP purchase $40 million in common stock at the IPO price of $16.00 per share.
• The Board conducted a self-evaluation process for 2024 and concluded that the Board and its committees are operating effectively.
• The 2024 corporate goals were achieved at 105%, leading to performance bonuses for executive officers.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating stable corporate governance and routine operations. It highlights successful capital raises and positive board self-evaluation, along with achievement of corporate goals at 105%. There are no negative operational or financial surprises, suggesting a generally positive and well-managed corporate environment, though it lacks specific forward-looking operational news.

Positives

• The Board of Directors and its committees concluded that they are operating effectively based on their 2024 self-evaluation process.
• A majority of the company's directors are independent, aligning with Nasdaq Listing Rules.
• The appointment of Sapna Srivastava as lead independent director in June 2025 enhances board independence and oversight.
• The company has a robust risk oversight process, administered directly by the Board and through its standing committees.
• Executive compensation policies are designed to align with stockholder interests and support strategic objectives, providing appropriate rewards and incentives.
• The company adopted a compensation recovery policy (clawback) in June 2024, demonstrating commitment to good governance.
• An insider trading policy is in place, prohibiting derivatives, hedging transactions, margin accounts, and pledging of company securities.
• The company achieved 105% of its pre-established 2024 corporate goals, leading to performance bonuses for executive officers.
• Significant capital was raised through preferred stock financings in 2023 ($90 million) and 2024 (approx. $259 million), and a concurrent private placement ($40 million), indicating investor confidence and funding for operations.

Risks

• The Board is responsible for monitoring and assessing strategic risk exposure, including determining the nature and level of risk appropriate for the company.
• The Audit Committee considers and discusses major financial risk exposures and steps to monitor and control them, including cyber-security risk.
• The Compensation Committee assesses and monitors whether compensation policies and programs have the potential to encourage excessive risk taking.

Future Outlook

The document primarily focuses on corporate governance, executive compensation, and past financial activities, particularly capital raises. It does not provide explicit forward-looking financial guidance or strategic outlook for the company's operations or product pipeline. However, it does detail performance-based equity awards for executives with share price targets of $46.75, $70.125, and $93.50 to be met within four, five, and six years, respectively, indicating internal long-term share price aspirations tied to executive incentives.

Management Comments

• "You are cordially invited to attend our Annual Meeting via our virtual meeting platform. Whether or not you expect to attend the meeting, please vote over the telephone or the internet prior to the Annual Meeting as instructed in these materials, or, if you receive a paper proxy card by mail, by completing and returning such proxy card promptly in order to ensure your representation at the Annual Meeting. Even if you have voted by proxy, you may still vote at the Annual Meeting." Martin Babler, President, Chief Executive Officer.

Industry Context

Alumis Inc. operates within the biopharmaceutical industry, as evidenced by the extensive experience of its directors and executive officers in this sector, including prior roles at major companies like Genentech, Sanofi, Celgene, Amgen, and AstraZeneca. The company's recent merger with ACELYRIN, Inc. (mentioned in director Lynn Tetrault's biography) indicates strategic consolidation within the industry, a common trend for growth and pipeline expansion. The company's significant capital raises through preferred stock financings and a private placement reflect the capital-intensive nature of biopharmaceutical R&D and commercialization, and investor appetite for companies in this space.

Comparison to Industry Standards

• Executive base salaries are established considering competitive market compensation paid by other companies for similar positions within the biopharmaceutical industry and geography.
• The company's board composition, with a majority of independent directors and the appointment of a lead independent director, aligns with best practices for corporate governance in publicly traded companies, including those in the biopharmaceutical sector.
• The adoption of a compensation recovery policy (clawback) and an insider trading policy prohibiting hedging and pledging aligns with evolving corporate governance standards and regulatory expectations for public companies, including those in the biotechnology industry.

Management Changes

Corporate Governance

Related Party Transactions

• Voting and Support Agreements: On February 6, 2025, entities affiliated with Foresite Capital Management, AyurMaya Capital Management Fund, LP, Samsara BioCapital, LP, and Martin Babler (collectively holding approximately 62% of outstanding capital stock) entered into agreements to vote their shares in favor of adopting the Merger Agreement and approving the issuance of shares in connection with the ACELYRIN merger.
• Foresite Labs Services Agreement: Entered in January 2021 (amended August 2021, December 2023) with Foresite Labs, LLC, an entity affiliated with Foresite Capital Management (a >5% stockholder). Foresite Labs provides data, analytics, and scientific support. $0.9 million was recognized as research and development expenses under this agreement in 2024.
• Series B-2 and B-2A Convertible Preferred Stock Financing: In May and October 2023, the company raised $90 million by issuing preferred stock. Participants included AyurMaya Capital Management Fund, LP, entities affiliated with BBA (including former director Julian C. Baker), and entities affiliated with Foresite Capital Management (including director James B. Tananbaum), all of whom are >5% stockholders or affiliated with directors.
• Series C and C-1 Convertible Preferred Stock Financing: In March and May 2024, the company raised approximately $259 million by issuing preferred stock. Participants included AyurMaya Capital Management Fund, LP, entities affiliated with Baker Brothers Life Sciences, L.P., entities affiliated with Foresite Capital Management, Samsara BioCapital, LP (including director Srinivas Akkaraju), and venBio Global Strategic Fund IV, L.P. (including former director Richard Gaster), all of whom are >5% stockholders or affiliated with directors.
• Concurrent Private Placement: In July 2024, AyurMaya Capital Management Fund, LP, an existing >5% stockholder affiliated with director Alan Colowick, purchased $40 million in common stock at the IPO price of $16.00 per share.
• Investors Rights Agreement: The company is party to an amended and restated investors rights agreement with >5% stockholders and entities affiliated with certain directors, granting registration rights. A right of first refusal under this agreement terminated upon the IPO.
• Employment Agreements and Stock Option Grants to Directors and Executive Officers: The company has entered into employment agreements with named executive officers and granted stock options to them and certain directors, as detailed in the Executive and Director Compensation section.

Stakeholder Impact

• Shareholders: Will vote on key governance matters (director elections, auditor ratification) at the Annual Meeting. Their ownership percentages are detailed, including significant holdings by institutional investors and management. The capital raises dilute existing shareholders but provide funding for company operations. The compensation recovery policy and insider trading policy aim to protect shareholder interests.
• Employees: Benefit from competitive compensation, equity awards (stock options, restricted stock), and employee benefit plans including a 401(k) plan, medical, dental, vision, disability, and life insurance.
• Management/Executives: Receive substantial compensation packages, including base salary, performance bonuses, and equity awards designed to align their interests with long-term company performance. Their employment agreements include severance and change-in-control benefits.
• Directors: Receive cash retainers and equity grants for their service, with a new compensation policy effective February 2025. Their independence and oversight roles are emphasized.
• Creditors/Investors: The significant capital raises indicate the company's ability to secure funding, which is positive for its financial stability and ability to meet obligations. The detailed financial disclosures provide transparency.

Next Steps

• Stockholders are urged to submit their votes in advance via internet, telephone, or mail for the Annual Meeting.
• The Annual Meeting will be held virtually on July 30, 2025, where stockholders can listen, submit questions, and vote online.
• Preliminary voting results will be announced at the Annual Meeting, with final results to be published in a Form 8-K filed with the SEC within four business days after the meeting.
• Stockholders wishing to submit proposals for the 2026 Annual Meeting under Rule 14a-8 must do so by February 16, 2026.
• Stockholders wishing to submit proposals or nominate directors for the 2026 Annual Meeting outside of Rule 14a-8 must deliver notice between April 1, 2026, and May 1, 2026.

Key Dates

Recommendation

Keywords

Alumis Inc., Proxy Statement, Annual Meeting, Corporate Governance, Board of Directors, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, Biopharmaceutical, Capital Raise, Stock Options, Risk Management, Related Party Transactions